| Christi Sue Catalano Strickler, RN, MSN, CRNA | |
|
111 S Front St, Harrisburg, PA 17101 | |
| (717) 782-3282 | |
| (717) 231-8964 |
| Full Name | Christi Sue Catalano Strickler |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 111 S Front St, Harrisburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487067641 | NPI | - | NPPES |
| 103449770 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN508478L (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Gettysburg Hospital | 2769373331 | 46 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Riverside Anesthesia Associates, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205827359 PECOS PAC ID: 6305758038 Enrollment ID: O20031103000137 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Summit Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306840814 PECOS PAC ID: 5496659484 Enrollment ID: O20031121000259 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | The Gettysburg Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366472706 PECOS PAC ID: 2769373331 Enrollment ID: O20040323000809 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Wood & Myers Oral And Maxillofacial Surgery, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437198405 PECOS PAC ID: 6901877729 Enrollment ID: O20040804001542 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Capital Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447210737 PECOS PAC ID: 9032188610 Enrollment ID: O20040930000090 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Upmc Pinnacle Hospitals |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407813603 PECOS PAC ID: 3971417874 Enrollment ID: O20060420000395 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Entity Name | Upmc Pinnacle Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730693979 PECOS PAC ID: 1951662980 Enrollment ID: O20180307001977 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christi Sue Catalano Strickler, RN, MSN, CRNA 111 S Front St, Harrisburg, PA 17101-2010 Ph: () - | Christi Sue Catalano Strickler, RN, MSN, CRNA 111 S Front St, Harrisburg, PA 17101 Ph: (717) 782-3282 |
News Archive
Patients suffering from conditions as diverse as asthma and diabetes could benefit from research at Cardiff University to improve the effectiveness of drugs taken through spray inhalers.
Compact in design - MEDIAJET from INTEGRA offers the unique flexibility to fill Petri dishes of various sizes, Petri dishes with two compartments or test tubes of various diameters and length.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.
› Verified 9 days ago
Mrs. Holly Ann Maley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-5118 Fax: 717-782-5854 | |
Ms. Alicia K Stidfole, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-5118 Fax: 717-782-5854 | |
Diane E Geise, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-5470 Fax: 717-782-5820 | |
Jessica E Rybinski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-231-8919 | |
Slim Ben M Aouadhi, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4300 Londonderry Rd, Harrisburg, PA 17109 Phone: 717-782-5118 Fax: 717-782-5854 | |
Jonathan D Humbert, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-3282 Fax: 717-231-8964 | |
Maria R Symonies, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-782-5470 Fax: 717-782-5820 |